OAM
CODX

Oxford Asset Management’s Co-Diagnostics CODX Stock Holding History

Oxford Asset Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-350
Closed -$30K – 1650
2017
Q4 		$30K Buy
+350
New +$52.4K ﹤0.01% 1578

Other funds holding CODX

HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Oxford Asset Management's CODX Position: Q1 2018 in Review

Oxford Asset Management sold out of Co-Diagnostics (CODX) in Q1 2018, closing a stake of 350 shares — an estimated $30K sold.

Oxford Asset Management first reported a position in CODX in Q4 2017 and held it in 1 quarter. The position peaked at $30K in Q4 2017. 8 funds tracked by Wall St. Rank hold CODX as of Q1 2018.

  • Oxford Asset Management reported no remaining Co-Diagnostics position as of Q1 2018 after selling out during the quarter.
  • Oxford Asset Management sold 350 Co-Diagnostics shares in Q1 2018, an estimated $30K.
  • Oxford Asset Management first reported a position in Co-Diagnostics in Q4 2017 and held it in 1 quarter.
  • Oxford Asset Management's Co-Diagnostics position peaked at $30K in Q4 2017.
  • 8 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2018.

Based on Oxford Asset Management's 13F filing for Q1 2018, filed 15 May 2018.